Pacific Biosciences Of California (PACB) EBITDA Margin (2010 - 2026)
Pacific Biosciences Of California's quarterly EBITDA Margin came in at 23.88% in Q1 2026, up 112304.0% year-on-year from N/an in Q1 2025, and up 73.56% quarter-over-quarter from 90.33% in Q4 2025.
Pacific Biosciences Of California has reported EBITDA Margin for 17 years, with the latest figure at 23.88% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 112304.0% year-over-year to 23.88%; the trailing twelve-month figure through Mar 2026 stood at 80.67% (up 35059.0% YoY), and the FY2025 full-year result was 341.45%, down 14040.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 23.88%, up from 90.33% in the prior quarter.
- The five-year high for EBITDA Margin was 3.16% in Q4 2024, with the low at 1146.92% in Q1 2025.
- Average EBITDA Margin over 5 years is 230.6%, with a median of 148.39% recorded in 2023.
- Year-over-year, EBITDA Margin sank 94413 bps in 2025 and surged 112304 bps in 2026.
- Tracing PACB's EBITDA Margin over 5 years: stood at 303.03% in 2022, then jumped by 55 bps to 137.02% in 2023, then surged by 102 bps to 3.16% in 2024, then slumped by 2957 bps to 90.33% in 2025, then jumped by 74 bps to 23.88% in 2026.
- The last three EBITDA Margin figures came in at 23.88% (Q1 2026), 90.33% (Q4 2025), and 98.47% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | -23.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.88% |
| Dec 31, 2025 | -90.33% |
| Sep 30, 2025 | -98.47% |
| Jun 30, 2025 | -105.73% |
| Mar 31, 2025 | -1,146.92% |
| Dec 31, 2024 | 3.16% |
| Sep 30, 2024 | -146.74% |
| Jun 30, 2024 | -481.87% |
| Mar 31, 2024 | -202.79% |
| Dec 31, 2023 | -137.02% |
| Sep 30, 2023 | -118.55% |
| Jun 30, 2023 | -148.39% |
| Mar 31, 2023 | -218.96% |
| Dec 31, 2022 | -303.03% |
| Sep 30, 2022 | -240.70% |
| Jun 30, 2022 | -205.17% |
| Mar 31, 2022 | -254.72% |
| Dec 31, 2021 | -195.57% |
| Jun 30, 2021 | -134.21% |
| Mar 31, 2021 | -301.57% |
| Dec 31, 2020 | 276.02% |
| Sep 30, 2020 | -124.90% |
| Jun 30, 2020 | -133.94% |
| Mar 31, 2020 | 8.25% |
| Dec 31, 2019 | -0.35% |
| Sep 30, 2019 | -132.92% |
| Jun 30, 2019 | -99.85% |
| Mar 31, 2019 | -184.37% |
| Dec 31, 2018 | -157.79% |
| Sep 30, 2018 | -137.95% |
| Jun 30, 2018 | -104.36% |
| Mar 31, 2018 | -124.91% |
| Dec 31, 2017 | -83.38% |
| Sep 30, 2017 | -93.47% |
| Jun 30, 2017 | -127.30% |
| Mar 31, 2017 | -95.83% |
| Dec 31, 2016 | -74.05% |
| Sep 30, 2016 | -69.76% |
| Jun 30, 2016 | -89.11% |
| Mar 31, 2016 | -100.93% |
| Dec 31, 2015 | -3.92% |
| Sep 30, 2015 | 13.04% |
| Jun 30, 2015 | -47.87% |
| Mar 31, 2015 | -114.29% |
| Dec 31, 2014 | -112.33% |
| Sep 30, 2014 | -44.52% |
| Jun 30, 2014 | -167.28% |
| Mar 31, 2014 | -162.19% |
| Dec 31, 2013 | -188.61% |
| Sep 30, 2013 | -275.89% |
| Jun 30, 2013 | -338.69% |
| Mar 31, 2013 | -378.68% |
| Dec 31, 2012 | -369.26% |
| Sep 30, 2012 | -819.09% |
| Jun 30, 2012 | -309.24% |
| Mar 31, 2012 | -273.98% |
| Dec 31, 2011 | -68.69% |
| Sep 30, 2011 | -300.09% |
| Jun 30, 2011 | -11,613.02% |
| Mar 31, 2011 | -12,883.33% |
| Dec 31, 2010 | -13,067.50% |
| Sep 30, 2010 | -18,498.18% |
| Jun 30, 2010 | -5,194.75% |